Osteoarthritis is the most common musculoskeletal disease and is characterized by cartilage destruction, osteophyte formation, subchondral bone sclerosis and cysts. Modern treatment strategies, as well as preventive measures, include early detection and knowledge of the early course of the disease. This includes how stress patterns, physical activity, impaired function and metabolic changes and other comorbidities affect development and possible associations with osteoarthritis.
The overall objective was to study the early development of osteoarthritis of the knee and its association with hand- and general osteoarthritis, metabolic diseases, biomarkers, long-term pain, physical function and stress patterns
BMI (kg/m2) — At baseline weight (kg) and height (m) are meassured and BMI will be calculated
BMI (kg/m2) — At 2 years follow-up weight (kg) and height (m) are meassured and BMI will be calculated
BMI (kg/m2) — At 5 years follow-up weight (kg) and height (m) are meassured and BMI will be calculated
Abdominal circumference (cm) — At baseline Abdominal circumference are meassured with measuring tape at navel height
Abdominal circumference (cm) — At 2 years follow-up Abdominal circumference are meassured with measuring tape at navel height
Abdominal circumference (cm) — At 5 years follow-up Abdominal circumference are meassured with measuring tape at navel height
Body composition — At baseline Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat
Body composition — At 2 years follow-up Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat
Body composition — At 5 years follow-up Body composition are assessed by Inbody 770, which gives data on proportion of muscle and body fat (separate meassures on visceral fat
Glucos — At Baseline Fasting glucos (mmol/L) meassured in serum
Glucos — At 1 year follow-up Fasting glucos (mmol/L) meassured in serum
Glucos — At 2 years follow-up Fasting glucos (mmol/L) meassured in serum
Glucos — At 3 years follow-up Fasting glucos (mmol/L) meassured in serum
Glucos — At 4 years follow-up Fasting glucos (mmol/L) meassured in serum
Glucos — At 5 years follow-up Fasting glucos (mmol/L) meassured in serum
HbA1c — At baseline HbA1c (mmol/mol) meassured in serum
HbA1c — At 1 year follow-up HbA1c (mmol/mol) meassured in serum
HbA1c — At 2 years follow-up HbA1c (mmol/mol) meassured in serum
HbA1c — At 3 years follow-up HbA1c (mmol/mol) meassured in serum
HbA1c — At 4 years follow-up HbA1c (mmol/mol) meassured in serum
HbA1c — At 5 years follow-up HbA1c (mmol/mol) meassured in serum
Total-cholesterol — At baseline Total-cholesterol (mmol/L) meassured in serum
Total-cholesterol — At 1 year follow-up Total-cholesterol (mmol/L) meassured in serum
Total-cholesterol — At 2 years follow-up Total-cholesterol (mmol/L) meassured in serum
Total-cholesterol — At 3 years follow-up Total-cholesterol (mmol/L) meassured in serum
Total-cholesterol — At 4 years follow-up Total-cholesterol (mmol/L) meassured in serum
Total-cholesterol — At 5 years follow-up Total-cholesterol (mmol/L) meassured in serum
Triglycerides — At baseline Triglycerides (mmol/L) meassured in serum
Triglycerides — At 1 year follow-up Triglycerides (mmol/L) meassured in serum
Triglycerides — At 2 years follow-up Triglycerides (mmol/L) meassured in serum
Triglycerides — At 3 years follow-up Triglycerides (mmol/L) meassured in serum
Triglycerides — At 4 years follow-up Triglycerides (mmol/L) meassured in serum
Triglycerides — At 5 years follow-up Triglycerides (mmol/L) meassured in serum
LDL-cholesterol — At baseline LDL-cholesterol (mmol/L) meassured in serum
LDL-cholesterol — At 1 year follow-up LDL-cholesterol (mmol/L) meassured in serum
LDL-cholesterol — At 2 years follow-up LDL-cholesterol (mmol/L) meassured in serum
LDL-cholesterol — At 3 years follow-up LDL-cholesterol (mmol/L) meassured in serum
LDL-cholesterol — At 4 years follow-up LDL-cholesterol (mmol/L) meassured in serum
LDL-cholesterol — At 5 years follow-up LDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At baseline HDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At 1 year follow-up HDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At 2 years follow-up HDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At 3 years follow-up HDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At 4 years follow-up HDL-cholesterol (mmol/L) meassured in serum
HDL-cholesterol — At 5 years follow-up HDL-cholesterol (mmol/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At baseline sensitive CRP (g/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At 1 year follow-up sensitive CRP (g/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At 2 years follow-up sensitive CRP (g/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At 3 years follow-up sensitive CRP (g/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At 4 years follow-up sensitive CRP (g/L) meassured in serum
Sensitive C-Reactive Protein (CRP) — At 5 years follow-up sensitive CRP (g/L) meassured in serum
Interleukin-1 (IL-1) — At baseline IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-1 (IL-1) — At 1 year follow-up IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-1 (IL-1) — At 2 years follow-up IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-1 (IL-1) — At 3 years follow-up IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-1 (IL-1) — At 4 years follow-up IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-1 (IL-1) — At 5 years follow-up IL-1 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At baseline IL-6 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At 1 year follow-up IL-6 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At 2 years follow-up IL-6 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At 3 years follow-up IL-6 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At 4 years follow-up IL-6 (pg/mL) meassured in plasma with ELISA
Interleukin-6 (IL-6) — At 5 years follow-up IL-6 (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At baseline TNF-alfa (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At 1 year follow-up TNF-alfa (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At 2 years follow-up TNF-alfa (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At 3 years folllow-up TNF-alfa (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At 4 years follow-up TNF-alfa (pg/mL) meassured in plasma with ELISA
Tumor Necrosis Factor-alfa (TNF-alfa) — At 5 years follow-up TNF-alfa (pg/mL) meassured in plasma with ELISA
Leptin — At baseline Leptin (ng/mL) meassured in serum with ELISA
Leptin — At 1 year follow-up Leptin (ng/mL) meassured in serum with ELISA
Leptin — At 2 years follow-up Leptin (ng/mL) meassured in serum with ELISA
Leptin — At 3 years follow-up Leptin (ng/mL) meassured in serum with ELISA
Leptin — At 4 years follow-up Leptin (ng/mL) meassured in serum with ELISA
Leptin — At 5 years follow-up Leptin (ng/mL) meassured in serum with ELISA
Galectin-1 — At baseline Galectin-1 (ng/mL) meassured in plasma with ELISA
Galectin-1 — At 1 year follow-up Galectin-1 (ng/mL) meassured in plasma with ELISA
Galectin-1 — At 2 years follow-up Galectin-1 (ng/mL) meassured in plasma with ELISA
Galectin-1 — At 3 years follow-up Galectin-1 (ng/mL) meassured in plasma with ELISA
Galectin-1 — At 4 years follow-up Galectin-1 (ng/mL) meassured in plasma with ELISA
Galectin-1 — At 5 years follow-up Galectin-1 (ng/mL) meassured in plasma with ELISA
One-leg rise — At baseline Knee strenght are assessed by one-leg rise
One-leg rise — At 2 years follow-up Knee strenght are assessed by one-leg rise
One-leg rise — At 5 years follow-up Knee strenght are assessed by one-leg rise
30s-chair stand test — At baseline Knee strenght are assessed by 30s-chair stand test
30s-chair stand test — At 2 years follow-up Knee strenght are assessed by 30s-chair stand test
30s-chair stand test — At 5 years follow-up Knee strenght are assessed by 30s-chair stand test
Maximal voluntary isometric contraction of Quadriceps — At baseline Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)
Maximal voluntary isometric contraction of Quadriceps — At 2 years follow-up Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)
Maximal voluntary isometric contraction of Quadriceps — At 5 years follow-up Maximal voluntary isometric contraction of Quadriceps assessed by dynamometer (N)
Hand strenght — At baseline Hand strenght are assessed by grippit (N)
Hand strenght — At 2 years follow-up Hand strenght are assessed by grippit (N)
Hand strenght — At 5 years follow-up Hand strenght are assessed by grippit (N)
Fitness — At 2 years follow-up Fitness are assessed by Åstrands test
Fitness — At 5 years follow-up Fitness are assessed by Åstrands test
Pain thresholds — At baseline pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia
Pain thresholds — At 2 years follow-up pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia
Pain thresholds — At 5 years follow-up pain threshold are assesed by computerized pressure algometry on eight predefined tender points out of the 18 points as part of the definition of fibromyalgia
Knee injury and osteoarthritis outcome score (KOOS) — At baseline KOOS consists of 5 subscales, assessing self reported knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Knee injury and osteoarthritis outcome score (KOOS) — At 1 year follow-up KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Knee injury and osteoarthritis outcome score (KOOS) — At 2 years follow-up KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Knee injury and osteoarthritis outcome score (KOOS) — At 3 years follow-up KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Knee injury and osteoarthritis outcome score (KOOS) — At 4 years follow-up KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Knee injury and osteoarthritis outcome score (KOOS) — At 5 years follow-up KOOS consists of 5 subscales, assessing knee pain, other Symptoms, Function in daily living (ADL), Function in sport and recreation (Sport/Rec) and knee related Quality of life (QOL).
Pain mannequin — At baseline Patient reported pain distribution
Pain mannequin — At 1 year follow-up Patient reported pain distribution
Pain mannequin — At 2 years follow-up Patient reported pain distribution
Pain mannequin — At 3 years follow-up Patient reported pain distribution
Pain mannequin — At 4 years follow-up Patient reported pain distribution
Pain mannequin — At 5 years follow-up Patient reported pain distribution
Pain intensity — At baseline Patient reported pain intensity by NRS scale 0-10 (best to worst)
Pain intensity — At 1 year follow-up Patient reported pain intensity by NRS scale 0-10 (best to worst)
Pain intensity — At 2 years follow-up Patient reported pain intensity by NRS scale 0-10 (best to worst)
Pain intensity — At 3 years follow-up Patient reported pain intensity by NRS scale 0-10 (best to worst)
Pain intensity — At 4 years follow-up Patient reported pain intensity by NRS scale 0-10 (best to worst)
Patient intensity — At 5 years follow-up Patient reported pain intensity by NRS scale 0-10 (best to worst)
Radiographic assessment of the knees — At baseline radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the knees — At 1 year follow-up radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the knees — At 2 years follow-up radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the knees — At 3 years follow-up radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the knees — At 4 years follow-up radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the knees — At 5 years follow-up radiographic assessment of tibiofemoral- and patellofemoral joint in the knee
Radiographic assessment of the hands — At 2 years follow-up Radiographic assessment of the hands.
Radiographic assessment of the hands — At 5 years follow-up Radiographic assessment of the hands.
Mechanical load — At inclusion Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days
Mechanical load — At 2 years follow-up Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days
Mechanical load — At 5 years follow-up Movement behavior measured with a triaxle accelerometer at work and leisure over 7 days
Trial sites (1)
Facility
City
Region
Status
Spenshult Research and Development center (FoU Spenshult)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
